Molecular Subtype
Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder
CI-CAN-00003733Explore in graph →
HematologicNon-malignant5 active trials
- NCIt
- C7195
Loading cancer entity…
Molecular Subtype
CI-CAN-00003733Explore in graph →
Clinical trials
13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03587844 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | recruiting | Phase 2 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2026source: clinicaltrials